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A Commentary on
Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between
2009 and 2018
by Vokinger, K. N., and Muehlematter, U. J. (2020). Health Policy 124, 261–267. doi: 10.1016/
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INTRODUCTION
In Switzerland, medical drugs undergo a two-step procedure before they have to be reimbursed
under mandatory basic health insurance: A drug must first be approved by Swissmedic, the Swiss
equivalent of the US Food and Drug Administration (FDA) and the European Medicines Agency
(EMA). Manufacturers may then request the approved drug to be included in the “specialities
list” (SL) of the Swiss Federal Office of Public Health (FOPH). Prerequisite for SL inclusion are
a favorable evaluation of the new drug’s efficacy and expediency and the negotiation of a maximum
price between FOPH andmanufacturer.With the successful SL inclusion begins the health insurers’
statutory obligation to reimburse the drug costs up to the agreed maximum price.
In their recent contribution “Accessibility of cancer drugs in Switzerland: Time from approval to
pricing decision between 2009 and 2018” (1), Vokinger andMuehlematter studied the time interval
between approval and SL inclusion of recent oncological drugs. A short interval is for the public
benefit because most patients are not capable of paying for costly cancer drugs out of their own
pockets before the drugs are included in the SL. Vokinger andMuehlematter came to the conclusion
that, to the detriment of patients, the time from approval to SL inclusion increased between 2009
and 2018.
METHODS AND RESULTS
Unfortunately, the analysis presented in their article is based on partially incorrect data due to
errors and inconsistencies in the original publications by the FOPH (2). For six substances, the SL
inclusion dates are incorrect (Carfilzomib: 2017 instead of 2018; Pembrolizumab: 2015 instead of
2017; Dabrafenib: 2014 instead of 2017; Trastuzumab emtansin: 2014 instead of 2017; Crizotinib:
2013 instead of 2017; Abiraterone: 2012 instead of 2017). The fact that five of these misspecified
inclusion years were assumed to be 2017 leads to an exaggerated peak at that particular year in
figure 2 of the original article.
Given the number of corrections, it seems worth re-analyzing the data and thereby also shed
some new light on its interpretation. For the following analyses, the opportunity was seized to
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FIGURE 1 | AFT model fit with 95% confidence and prediction intervals; solid line = mean, dotted line = median.
complete SL inclusion dates until re-submission of the
revised article (Niraparib: 2019; Histrelin: 2011), and to
add Ruxolitinib (approved 2012, included 2014), a substance
targeting hematological malignancies. Additionally, the set of
substances was restricted to drugs with a time period between
approval and pricing decision of no more than 3.5 years. This
time window was chosen so that the reduced set includes
Sonidegib with a maximum negotiation period of 1,097 days, and
at the same time takes account of the fact that longer negotiations
never reached a successful conclusion so far.
A naive linear regression model incorporating the remaining
64 drugs, with the approval date as independent and the time-
to-pricing decision as the dependent variable, reveals a non-
significant increase (p = 0.26) of the time-to-pricing decision
of 14.4 days per year. However, this approach is inappropriate,
since price negotiations for recently approved substances may
be ongoing which implies that these drugs get systematically
disregarded, and the 14.4 days therefore underestimate the
true increase.
Presumably, it was exactly for this reason that the authors
chose the SL inclusion date rather than the more intuitive
approval date as independent variable for their analyses and
presentation in their figure 3. However, this choice does not
fully exclude all bias since, inversely to the previous situation,
drugs approved before 2009 are missing among those with early
inclusion dates (2009 or shortly after), thus leading to possible
overestimation of the true yearly increase.
An obvious approach to account for censoring is to 
rely on survival analysis methodology and, in particular, to 
fit an accelerated failure time (AFT) model of the form 
log T = α + β · t + σ · ε with T = time-to-pricing decision 
(inclusion into SL), t = date of approval, and ε ∼ F (ε) 
= 1 − exp(− exp (ε)). This corresponds to T having a Weibull 
distribution with scale parameter σ and location parameter 
exp(α + β · t) in the location-scale parametrization of R’s survival 
package which was used for calculations. The fitted model reveals 
a yearly increase of the time-to pricing decision by 8.24% which 
is not significant on the 5% level (p = 0.087). Figure 1 
shows all data (including data censored at 25/11/2019 which is 
the re-submission date of the revised article, or 31/07/2019 for 
Olaratumab whose approval was revoked on said date before a 
price agreement had been reached) together with mean, median, 
confidence and prediction bands, and replaces figures 2, 3 of the 
original article (except for the rebate data).
DISCUSSION
Vokinger and Muehlematter found that the time-to-pricing 
decision has prolonged over the past 10 years. However, re-
analyzing the corrected data shows that the effect is neither 
overwhelming in size nor significant under the chosen AFT 
model assumptions. Moreover, it seems that both the numbers 
of drugs approved as well as the duration of pricing negotiations
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increased discontinuously with a particularly large step in mid-
2015, a singular effect which is not captured by the AFT model.
It would be interesting to study whether this is in response
to the evolution of cancer drug prices around that time, or
due to limited personnel resources at the FOPH, more complex
pricing negotiations with more frequently granted rebates,
or—hypothetically—even due to the FOPH exerting pressure
on the manufacturers by deliberately delaying market entry of
their products while asking prices seemed too high. It would
also be interesting to repeat the analysis once more data will
be available.
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